FIELD: medicine.
SUBSTANCE: the present innovation deals with affecting blood with the suggested preparations: under laboratory conditions one should apply 1 ml patient's blood stabilized with 3.8%-sodium citrate solution at the ratio of 1:9 to be introduced by drops at the quantity of 0.1-0.2 ml and mixed. A timing device should be applied and in case of blood clots for 1 min, not longer it is possible to conclude upon the presence of hemostatic effect. The innovation enables to shorten the period for investigation at increased significance of the results obtained.
EFFECT: higher accuracy of evaluation.
3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTISEPTIC DRUG WITH HAEMOSTATIC ACTION, AND METHOD FOR PREPARING IT | 2011 |
|
RU2508104C2 |
| METHOD FOR COMPARATIVE STUDY OF THE EFFECTIVENESS OF LOCAL HAEMOSTATIC AGENTS IN EXPERIMENT IN VITRO | 2019 |
|
RU2709517C1 |
| METHOD FOR DETERMINATION OF SUITABILITY OF HEMOSTATIC SPONGE PREPARATION FOR USE IN PERFORMANCE OF HEMOSTASIS | 1988 |
|
SU1564781A1 |
| SOFT HEMOSTATIC DOSAGE FORM WITH NANOPARTICLES | 2019 |
|
RU2711616C1 |
| METHOD OF USING FISH SKIN MUCUS FOR ACTIVATION OF PLATELET AGGREGATION AND BLOOD CLOTTING IN VITRO | 2017 |
|
RU2652444C1 |
| LOCAL HEMOSTATIC ANTIBACTERIAL AGENT, METHOD FOR PRODUCTION THEREOF, AND MEDICAL PRODUCT BASED THEREON | 2020 |
|
RU2756316C1 |
| HEMOSTATIC SPONGE AND METHOD OF ITS PRODUCTION | 2016 |
|
RU2628809C1 |
| TEST SYSTEM FOR PERFORMING HAEMOSTATIC PROPERTIES OF LOCAL WOUND COATINGS IN VITRO | 2019 |
|
RU2695075C1 |
| HEMOSTATIC SPONGE (VERSIONS) | 2016 |
|
RU2627855C1 |
| HEMOSTATIC AGENT BASED ON CHITOSAN | 2023 |
|
RU2807862C1 |
